Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
According to the National Psoriasis Foundation, approximately 30% of people who have psoriasis are also affected by psoriatic arthritis globally. This constitutes around 37.5 million people around the world. There are several various types of psoriatic arthritis, therefore finding effective solutions for the disease often requires multiple clinical trials. Several medications are in the pipeline and companies are developing effective and innovative treatments to manage the disease.
The Psoriatic Arthritis Drug Pipeline Report by Expert Market Research gives comprehensive insights into ongoing psoriatic arthritis clinical trials. It covers various aspects related to the details of psoriatic arthritis drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The psoriatic arthritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from psoriatic arthritis.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing psoriatic arthritis pipeline development activities are covered. Moreover, psoriatic arthritis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Psoriatic arthritis is a type of arthritis that is linked to psoriasis. Psoriasis is a chronic skin condition characterized by skin rashes, joint pain, stiffness, and changes in fingernails and toenails. Psoriatic arthritis has similar symptoms to rheumatoid arthritis , but it affects fewer joints than rheumatoid arthritis. There are several types of psoriatic arthritis and can be divided into five categories which include arthritis affecting small joints in the toes and fingers, asymmetrical arthritis of the joints in the hands, symmetrical polyarthritis, and arthritis mutilans (a rare type of arthritis that deforms joints) and psoriatic spondylitis which affects the lower back and spine.
The common symptoms of psoriatic arthritis include joint pain, stiffness, and redness near affected joints, swelling in fingers, pain where tendons and ligaments attach to the bones, silver or gray scaly patches on the scalp, knees, and elbows, knees, and discoloration or pitting on fingernails among others. The psoriatic arthritis treatment options include anti-inflammatory medicine like NSAIDs or acetaminophen, corticosteroids, cold or heat therapy, disease-modifying antirheumatic drugs (DMARDs) and physical therapy.
Several pharma companies and institutes are developing innovative treatments to manage psoriatic arthritis. There have been significant increases in the treatment options for psoriatic arthritis. Between 2013 and 2017, the FDA approved three new drugs to manage and treat psoriatic arthritis after clinical trials showed positive results. Researchers are exploring potential new therapies in clinical trials to manage the disease, thus impacting the psoriatic arthritis pipeline analysis.
This section of the report covers the analysis of psoriatic arthritis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s psoriatic arthritis therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for psoriatic arthritis with 108 pipeline drugs in phase III.
The drug molecule categories covered under psoriatic arthritis pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapy. Gene therapy is a promising treatment for arthritis. It is an experimental technique to treat or prevent disease by introducing genetic material into cells to compensate for abnormal genes and replacing them with a healthy copy of the gene. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for psoriatic arthritis.
The EMR psoriatic arthritis drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Psoriatic Arthritis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for psoriatic arthritis. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of psoriatic arthritis drug candidates.
Drug: Izokibep
The trial is designed to evaluate the safety and effectiveness of Izokibep which is a selective inhibitor of interleukin (IL)-17A for the treatment of psoriatic arthritis (PsA). The trial is sponsored by Hansoh BioMedical R&D Company and is currently under phase II.
Drug: HS-10374
The objective of the study is to explore the clinical safety and effectiveness of HS-10374 for the treatment of active psoriatic arthritis. The trial is sponsored by ACELYRIN Inc. and is currently under phase III.
Biological: Secukinumab
Novartis Pharmaceuticals is developing this psoriatic arthritis drug candidate and it is currently under phase III. The study is being conducted to compare the safety and effectiveness of secukinumab and ustekinumab in patients with active psoriatic arthritis.
The Psoriatic Arthritis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for psoriatic arthritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into psoriatic arthritis collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Psoriatic Arthritis Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
Scope of the Report | Details |
Drug Pipeline by Clinical Trial Phase |
|
Route of Administration |
|
Drug Classes |
|
Leading Sponsors Covered |
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share